Effect of nebulized arformoterol on airway function in COPD: Results from two randomized trials

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 5, Issue 1, 2008, Pages 25-34

  Hanrahan, John P ^a   Hanania, Nicola A ^b   Calhoun, William J ^c   Sahn, Steven A ^d   Sciarappa, Kenneth ^a   Baumgartner, Rudolf A ^a  

^a SUNOVION PHARMACEUTICALS INC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Chronic obstructive pulmonary disease; Inhalation solution; Long acting 2 agonists; Lung function; Placebo controlled; Pulmonary function testing

Indexed keywords

ARFORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; IPRATROPIUM BROMIDE; LONG ACTING DRUG; SALBUTAMOL; SALMETEROL;

ADULT; AGED; AORTA DISSECTION; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISSEMINATED CANCER; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HUMAN; INSOMNIA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; NEBULIZATION; NERVOUSNESS; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SINGLE BLIND PROCEDURE; TACHYCARDIA; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 38949204853     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550701816187     Document Type: Article

References (18)

1. Mannino DM. Chronic obstructive pulmonary disease: definition and epidemiology. Respir Care 2003; 48:1185-1191.
2. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J of Respir Crit Care Med 1995; 152:S77-S121.
3. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J of Respir Crit Care Med 2001; 163:1256-1276.
4. O'Donohue WJ and the National Association for Medical Direction of Respiratory Care (NAMDRC) Consensus Group. Guidelines for the use of nebulizers in the home and at domiciliary sites. Chest 1996; 109:814-820.
5. European Respiratory Task Force. European Society Guidelines on the use of nebulizers. Eur Respir J 2001; 18:228-242.
6. Trofast J, Osterberg K, Kallstrom BL, Waldeck B. Steric aspects of agonism and antagonism at beta-adrenoceptors: synthesis of and pharmacological experiments with the enantiomers of formoterol and their diastereomers. Chirality 1991; 3:443-450.
7. Handley DA, Senanayake CH, Dutczak W, Benovic JL, Walle T, Penn RB, Wilkinson HS, Tanoury GJ, Andersson RG, Johansson F, Morley J. Biological actions of formoterol isomers. J. Pulm Pharmacol Ther 2002; 15:135-145.
8. 2-agonists on ACh release and smooth muscle contraction in trachea. Am J Physiol 1998; 274:L32-38.
9. Schmidt D, Kallstrom BL, Waldeck B, Branscheid D, Magnussen H, Rabe KF. The effect of the enantiomers of formoterol on inherent and induced tone in guinea-pig trachea and human bronchus. Naunyn Schmiedebergs Arch Pharmacol 2000; 361:405-409.
10. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. http://www.wma.net/e/policy/b3.htm
11. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123:659-664.
12. Bestall JC , Paul EA, Garrod R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54:581-586.
13. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982; 38:29-41.
14. Donohue JF. Minimal clinically important differences in COPD lung function. COPD: J Chronic Obstructive Pul Dis 2005; 2:111-124.
15. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
16. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144:904-912.
17. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New Eng J Med 2007; 356:775-789.
18. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, Guyatt G; American College of Chest Physicians; American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005; 127:335-371.